Posted on 29/01/2010 in Pharmaceutical Company Financials AstraZeneca this week posted its financial results for the whole of 2009, revealing that its core operating profit for the full year increased by 23 per cent to $13,621 million (8.43 million pounds).
The firm's emerging markets revenue was up by 12 per cent, constituting around 13 per cent of total company revenue for the 12-month period.
Additionally, the organisation's revenue in the fourth quarter increased by four per cent, while core earnings per share also rose by seven per cent.
David Brennan, chief executive officer, said that these figures show that the company delivered a strong performance last year.
He continued: "We now have five products awaiting regulatory approval and have added four significant late-stage development projects through our externalisation efforts. Our plans for the next five years confirm our commitment to research-based, innovative biopharmaceuticals."
In other AstraZeneca news, scientific instruments provider Dako revealed this week that the two firms are set to collaborate in order to develop companion diagnostic tests for multiple oncology projects.Other news stories from 29/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
